Degarelix

Degarelix is a synthetic decapeptide GnRH receptor antagonist that produces immediate and profound suppression of testosterone without the initial stimulatory phase (flare) characteristic of GnRH agonists. This direct antagonist mechanism provides important advantages in situations where avoiding testosterone surge is clinically significant.

The compound incorporates numerous non-natural amino acids strategically positioned to maximize receptor binding affinity while minimizing the histamine-releasing activity that limited earlier GnRH antagonists. These structural modifications enable subcutaneous depot administration with acceptable local tolerability.

Unlike GnRH agonists that require 2-4 weeks to achieve testosterone suppression, degarelix reduces testosterone to castrate levels within days of the first injection. This rapid onset is particularly valuable in prostate cancer patients with impending spinal cord compression or urinary obstruction, where testosterone flare could accelerate disease progression.

Clinical research has demonstrated degarelix achieves testosterone suppression comparable to GnRH agonists while potentially offering cardiovascular advantages. Studies suggest lower rates of cardiovascular events compared to agonist therapy, possibly related to differences in FSH suppression or other mechanistic distinctions. Research continues to evaluate optimal applications and comparative outcomes.